Monte Rosa Therapeutics, Inc
Monte Rosa Therapeutics is seeking a highly motivated Scientist I/II to join the In Vivo Pharmacology team, generating in vivo and translational immunology data to guide molecular glue degrader programs. The role involves designing, executing, and interpreting complex in vivo and ex vivo studies to evaluate target biology, pharmacodynamics, and mechanisms of action. This position requires strong expertise in flow cytometry and immune profiling, with opportunities to mentor junior team members and contribute to strategic research planning.
Monte Rosa Therapeutics is a biotechnology company pioneering molecular glue degrader (MGD) therapies that promote specific protein ubiquitination and subsequent proteasomal degradation of disease-causing, traditionally undruggable proteins. Their drug discovery platform integrates expertise in MGD chemistry, artificial intelligence, structural biology, and proteomics to rapidly advance programs targeting undruggable or inadequately drugged targets with unprecedented specificity. Focused on cancer and beyond, the company operates out of Boston, MA and Basel, Switzerland.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc didn’t post a salary, so this is our estimate from similar listings.
47% above the average for this role
Scientist, Bioscience Immunology
AstraZeneca
Principal Associate Scientist
Xaira Therapeutics
Associate Scientist / Scientist, Immunology & Pharmacology
PharmaEssentia
In Vivo Scientist
AstraZeneca
Scientist, Immunology & Pharmacology (Hematologic Malignancies)
PharmaEssentia
Research Scientist I/II
Iambic Therapeutics